Status:
TERMINATED
Pharmacokinetics of Progesterone in Pregnancy-2
Lead Sponsor:
Thomas Jefferson University
Conditions:
Pregnancy Related
Eligibility:
FEMALE
16-55 years
Phase:
PHASE1
Brief Summary
The objective of this study is to evaluate the local pharmacokinetics of progesterone in pregnancy through evaluation of progesterone levels in maternal serum, endometrium, and cordblood in pregnant p...
Detailed Description
The objective of this pilot study is to evaluate the local pharmacokinetics of progesterone in pregnancy through evaluation of progesterone levels in maternal serum, endometrium, and cordblood in preg...
Eligibility Criteria
Inclusion
- Age ≥18yo
- Singleton gestation, ≥36 0/7 weeks gestation
- Scheduled cesarean delivery at Thomas Jefferson University Hospital or affiliate
Exclusion
- Contraindication to vaginal progesterone suppository
- Active hepatic disease
- Prior or current thrombus
- Known adverse reaction to progesterone
- Peanut allergy
- Bleeding disorder (such as thrombophilia)
- Use of 17-hydroxyprogesterone caproate in the pregnancy
- Use of vaginal progesterone in the pregnancy
- History of adverse reaction to progesterone
- Current vaginitis
Key Trial Info
Start Date :
January 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT04753957
Start Date
January 7 2022
End Date
February 1 2022
Last Update
May 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107